IP Library Granted Patent US 8,163,912
Granted Patent B2
US 8,163,912 · App. 12/586,834 · Granted Apr 24, 2012

Berberine compounds and processes for the preparation of berberine compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,912
App. No.
12/586,834
Granted
Apr 24, 2012
Kind
B2
Abstract

The invention is directed to berberine compounds and processes for the preparation of berberine compounds through an intramolecular Bischler-Napieralski cyclization.

Claims (52)

1. A compound of Formula (II):

wherein:

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of cyano, hydroxyl, amino, hydrogen, halogen, hydrocarbyl, substituted hydrocarbyl, and OR 5 ;

R 5 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl; and

R 7 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl.

2. The compound of claim 1 , wherein the compound comprises a counter-ion selected from the group consisting of chloride, bromide, iodide, trifluoroacetate, trifluoromethanesulfonate, methanesulfonate, acetate, p-toluenesulfonate, sulfate, bisulfate, phosphate, hydrogenphosphate, dihydrogenphosphate, furmarate, malonate, oxalate, formate, tartrate, benzoate, and a combination thereof.

3. The compound of claim 1 , wherein:

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, substituted and unsubstituted acyl, alkenyl, alkoxy, alkoxyaryl, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, arylalkoxy, carboalkoxy, carboxyalkenyl, carboxyalkyl, carboxyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylether, haloalkoxy, haloalyl, heteroaryl, heterocyclic, hydroxyalkyl, and hydroxyl; and

R 7 is selected from the group consisting of hydrogen, alkyl, and aryl.

4. The compound of claim 1 , wherein: R 1 is halogen; R 2 is hydrogen; R 3 is OR 5 ; R 4 is hydroxyl; and R 7 is hydrogen.

5. A compound of Formula (IIa):

wherein:

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of cyano, hydroxyl, amino, hydrogen, halogen, hydrocarbyl, substituted hydrocarbyl, and OR 5 ; and

R 5 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl.

6. The compound of claim 5 , wherein the compound comprises a counter-ion selected from the group consisting of chloride, bromide, iodide, trifluoroacetate, trifluoromethanesulfonate, methanesulfonate, acetate, p-toluenesulfonate, sulfate, bisulfate, phosphate, hydrogenphosphate, dihydrogenphosphate, furmarate, malonate, oxalate, formate, tartrate, benzoate, and a combination thereof.

7. The compound of claim 5 , wherein: R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, substituted and unsubstituted acyl, alkenyl, alkoxy, alkoxyaryl, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, arylalkoxy, carboalkoxy, carboxyalkenyl, carboxyalkyl, carboxyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylether, haloalkoxy, haloalyl, heteroaryl, heterocyclic, hydroxyalkyl, and hydroxyl.

8. The compound of claim 5 , wherein: R 1 is halogen; R 2 is hydrogen; R 3 is OCH 3 ; and R 4 is hydroxyl.

9. A process for preparing a compound, the process comprising contacting a compound of Formula (I) with a proton donor and a proton donor anhydride, the molar ratio of proton donor to proton donor anhydride being from 5:1 to about 1:100, to form a compound of Formula (II) according to the following reaction scheme:

wherein:

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of cyano, hydroxyl, amino, hydrogen, halogen, hydrocarbyl, substituted hydrocarbyl, and OR 5 ;

R 5 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl; and

R 7 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl.

10. The process of claim 9 , wherein the molar ratio of proton donor to proton donor anhydride is from about 1:1 to about 1:20; the reaction is conducted at a temperature below about 15° C.;

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, substituted and unsubstituted acyl, alkenyl, alkoxy, alkoxyaryl, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, arylalkoxy, carboalkoxy, carboxyalkenyl, carboxyalkyl, carboxyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylether, haloalkoxy, haloalyl, heteroaryl, heterocyclic, hydroxyalkyl, and hydroxyl;

R 7 is selected from the group consisting of hydrogen, alkyl, and aryl; and

the proton donor is selected from the group consisting of benzenesulfonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, methanesulfonic acid, nitric acid, phosphoric acid, polyphoshoric acid, sulfuric acid, trichloroacetic acid, trifluoroacetic acid, p-toluenesulfonic acid, anhydrous hydrogen fluoride, fluorosulfonic acid, perchloric acid, perfluoroalkysulfonic acid, and combinations thereof; and the proton donor anhydride is an anhydride of a proton donor selected from the group consisting of benzenesulfonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, methanesulfonic acid, nitric acid, phosphoric acid, polyphoshoric acid, sulfuric acid, trichloroacetic acid, trifluoroacetic acid, p-toluenesulfonic acid, anhydrous hydrogen fluoride, fluorosulfonic acid, perchloric acid, perfluoroalkysulfonic acid, and combinations thereof.

11. The process of claim 9 , wherein the yield of the compound of Formula (II) is at least 80% by weight of the products formed.

12. The process of claim 9 , wherein the compound of Formula (I) of a compound corresponding to Formula (Ia):

and the compound of Formula (II) is a compound corresponding to Formula (IIa):

wherein:

R 1 , R 2 , R 3 , and R 4 are as defined in claim 9 .

13. The process of claim 12 , wherein the molar ratio of proton donor to proton donor anhydride is from about 1:2 to about 1:10; the reaction is conducted at a temperature below about 15° C.; R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, substituted and unsubstituted acyl, alkenyl, alkoxy, alkoxyaryl, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, arylalkoxy, carboalkoxy, carboxyalkenyl, carboxyalkyl, carboxyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylether, haloalkoxy, haloalyl, heteroaryl, heterocyclic, hydroxyalkyl, and hydroxyl; and the proton donor is selected from the group consisting of benzenesulfonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, methanesulfonic acid, nitric acid, phosphoric acid, polyphoshoric acid, sulfuric acid, trichloroacetic acid, trifluoroacetic acid, p-toluenesulfonic acid, anhydrous hydrogen fluoride, fluorosulfonic acid, perchloric acid, perfluoroalkysulfonic acid, and combinations thereof; and the proton donor anhydride is an anhydride of a proton donor selected from the group consisting of benzenesulfonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, methanesulfonic acid, nitric acid, phosphoric acid, polyphoshoric acid, sulfuric acid, trichloroacetic acid, trifluoroacetic acid, p-toluenesulfonic acid, anhydrous hydrogen fluoride, fluorosulfonic acid, perchloric acid, perfluoroalkysulfonic acid, and combinations thereof.

14. The process of claim 9 , wherein the compound of Formula (I) is a compound corresponding to Formula (Ib):

and the compound of Formula (II)is a compound corresponding to Formula (IIb):

15. The process of claim 14 , wherein the proton donor is trifluoromethanesulfonic acid and the proton donor anhydride is trifluoromethanesulfonic anhydride.

16. The process of claim 15 , wherein the ratio of trifluoromethanesulfonic acid to trifluoromethanesulfonic anhydride is from about 1:2 to about 1:10.

17. A process for preparing a compound, the process of contacting a compound of Formula (I) with a proton donor anhydride, wherein the equivalents of proton donor anhydride to the compound of Formula (I) is from about 1.5 to about 1000, to form a compound of Formula (II) according to the following reaction scheme:

wherein:

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of cyano, hydroxyl, amino, hydrogen, halogen, hydrocarbyl, substituted hydrocarbyl, and OR 5 ;

R 5 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl; and

R 7 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl.

18. The process of claim 17 , wherein the reaction is conducted at a temperature below about 15° C.; the yield of the compound comprising Formula (II) is at least 65% by weight of the products formed;

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, substituted and unsubstituted acyl, alkenyl, alkoxy, alkoxyaryl, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, arylalkoxy, carboalkoxy, carboxyalkenyl, carboxyalkyl, carboxyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylether, haloalkoxy, haloalyl, heteroaryl, heterocyclic, hydroxyalkyl, and hydroxyl; and

R 7 is hydrogen, alkyl, or aryl.

19. The process of claim 17 , wherein the compound of Formula (I) is a compound corresponding to Formula (Ia):

and the compound of Formula (II) is a compound corresponding to Formula (IIa):

wherein:

R 1 , R 2 , R 3 , and R 4 are as defined in claim 17 .

20. The process of claim 19 , wherein R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, substituted and unsubstituted acyl, alkenyl, alkoxy, alkoxyaryl, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, arylalkoxy, carboalkoxy, carboxyalkenyl, carboxyalkyl, carboxyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylether, haloalkoxy, haloalyl, heteroaryl, heterocyclic, hydroxyalkyl, and hydroxyl.

21. The process of claim 17 , wherein the compound of Formula (I) is a compound corresponding to Formula (Ib):

and the compound of Formula (II) is a compound corresponding to Formula (IIb):

22. The process of claim 21 , wherein the proton donor anhydride is trifluoromethanesulfonic anhydride.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2009
From: GROTE, CHRISTOPHER W.; MOSER, FRANK W.; JOHNSON, JOHN E.
To: MALLINCKRODT INC.
Reel/Frame 023396/0123 →